| Date |
Time |
Event |
Session 1: Current Innovation on neglected disease Drugs, vaccine development |
| Aug. 10th |
8:00 am |
1.1 Freddie Anne Hoffman M.D., Heterogeneity LLc. “Botanicals: A New Drug Industry for the United States Impact on Serious and Life-Threatening Conditions” |
| 8:30 am |
1.2. Rick Friedman Ph.D., Division of Compliance, CEDR, FDA
"Overview of the Updated FDA Compliance Program." |
| 9:00 am |
1.3 David L Pompliano, PhD, Dept. of Infectious Diseasses Merck Sharp & Dome "Merck Neglected Disease Pipeline”
Overview of Innovation Case Reporting on Neglected Diseases Drugs and Vaccine development challenges |
| 9:30 am |
1.4 Gio-Bin Lim Ph.D., Dept. of Chemical and Biochemical Engineering, The University of Suwon, Korea.
“Application of Supercritical Fluid Process for Drug Delivery Systems (DDS): Particles Formation for API” |
Session 2: Best Practices of Laboratory Innovations & Practices
–The innovative bioassay R & D |
| Aug. 10th |
11:00 am |
2.1 Kim Hong Yeoul, Ph.D. Biological Sciences of Oriental Medicine, Graduate School of Kyung Hee University.
“The polyphosphate kinase as a novel target for antimicrobial therapy (Cloning, Expression and Characterization of Polyphosphate Kinase from Mycobacterium tuberculosis and Mycobacterium leprae)” |
| 11:40 am |
2.2 Scott Franzblau, Ph. D. Director, Institute for Tuberculosis Research. “Discovery of natural product targets for Tuberculosis utilizing innovative Microbacterium Bioassay.” |
| 12:20 pm |
2.3 Larry Walker, Ph.D. Director of NCNPR, Dept of Pharmacology, University of Mississippi, School of Pharmacy.
“Bioassay systems for the Malaria and natural product drug discovery" |
| 12:50 pm |
2.4 Ulf Nehbass, Ph.D., CEO of Insitute de Pasteur Korea
“Bioassay system for Malaria, TB, HIV, Leishimaniasis and IP-Korea drug discovery program.” |
Session 3 : Best Practices of Good Manufacturing Practice (cGMP) of Biological, and genomic product innovation |
| Aug. 10th |
2:00 pm |
3.1 Kyo-Hoon Han, Ph.D., Protein Analysis & Design Laboratory, Korea Research Institute for Bioscience & Biotechnology
"NMR structural characterization of HBV preS1 surface antigen for better vaccines". |
| 2:30 pm |
3.2 Jung Keel Lee, Ph.D., Korea University, Good Manufacturing Practice Program in Korea University, Seoul, Korea.
“International GMP Inspection for Human Vaccine-WHO Pre-qualification International Training Institution Program Development in Korea.” |
| 3:00 pm |
3.3 Colin Newbould, CChem MRSC CSci. EN Pharma – UK
“Good Agricultural Practice (GAP) & Good Sourcing Practice (GSP) for Botanical Drugs identification and role QP roles and responsibilities accordance to EU & MRHA-UK Regulatory Compliance.” |
| 3:30 pm |
3.4 Charles Ahn, Ph.D., Enforcement Branch, DOC/CDER, FDA, "Highlights of cGMP Monitoring Activities." |
Session 4: Clinical Data Management and Good Clinical Practice (GCP/CTM) for multi-center study monitoring Case Studies and Reporting on Botanical Drugs, Biologics, innovative drug delivery designs/GCP Clinical Data Management |
| Aug. 11 |
8:00am |
4.1 Cecil Czerkinsky, D.D.M., Ph.D. International Vaccine Institute (IVI-Korea)
“Sublingual vaccination against respiratory pathogens”. |
| 8:30 am |
4.2 Dong Ouk Lee Ph.D, R & D Director, NKBio
Co., Ltd.
“The safety and efficacy of activated autologuous lymphocytes (Natural Killer Mixer Cell:NKM) infusions for the tratment of Malignant Lymphoma Phase II trial”. |
| 9:00 am |
4.3 P. Leszek D. Vincent Ph.D., FLS., University of Missouri, Columbia, MO.
Investigator for The International Center for Indigenous Phytotherapy Studies (TICIPS): “HIV/AIDS, Secondary Infections, and Immune Modulation of HIV Indigenous Botanical Drugs Used in South Africa”. |
| 9:30 am |
4.4 Glen Argyle Ph.D., Iberica USA
"Clinical Trial Management & Improving Multi-centered Clinical Site Quality" |
| 10:00 am |
4.5 Glen Park, Ph.D. Sr. Director, Clinical and Regulatory Affairs at Target Health Inc.
“Target Health Clinical Trial Pipeline and Regulatory compliance - Good Clinical Practice (GCP) Case Reporting on Pharmaceutical Neglected Drugs” |
Session 5: Cutting-Edge Biomedical Research at NEBS |
| Aug. 11 |
11:00 am |
5.1 Jee-Yeong Jeong, Ph.D., Postdoctoral Research Fellow. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA ,
“Erythropoietin and Erythropoietin Receptor in Cancer.” |
| 11:30 am |
5.2 Jeongsik Yong, Ph.D. Assistant Professor in research track, Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, Philadelphia, PA
“Assemby of RNA-protein complexes: lessons from neuromuscular disease” |
| 12:00 pm |
5.3 Kyuhyung Kim, Ph.D., Postdoctoral Research Fellow. Department of Biology, Brandeis University, Waltham, MA,
“A GPCR and CaMK cascade mediate the effects of dauer pheromone on dauer formation and gene expression.” |
Session 5b: Cutting-Edge Biomedical Research at NIH |
| Aug. 11 |
1:30 pm |
5.4 Beom-Su Jang, In Soo Shin, Seung Hee Park, Jin-Soo Maeng, Nhat Le, Sarah Yu, S. Narasimhan Danthi, Jianwu Xie, Brad Wood, Ira Pastan, Chang H. Paik, NIH, Bethesda, MD,
“Development and application of Radiolabeled integrin αVβ3 Antagonist for tumor detection and assessment of therapeutic response.” |
| 2:00 pm |
5.5 Yong-Sik Kim, PhD, Laboratory of Respiratory Biology, Cell Biology Section NIEHS/NIH,
“The Krüppel-like zinc finger transcription factors, Glis1-3 in development and disease” |
| 2:30 pm |
5.6 Dae-Sik Lim, Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Korea,
“Regulation of RASSF1A in the cell cycle progression” |
| 3:30 pm |
5.7 Tae-Young Roh, Laboratory of Molecular Immunology, NHLBI/NIH,
“Comprehensive characterization of histone modifications in the human genome” |
Session #6 : SBR/CKD Bioscience Award |
| |
TBA |
